AstraZeneca ends phase 3 cancer trial as bispecific underwhelms
AstraZeneca has stopped a phase 3 trial of volrustomig in lung cancer based on interim efficacy data, narrowing the…
GSK plans phase 3 after mRNA flu vaccine beats standard shots
GSK has linked its mRNA seasonal flu vaccine candidate to higher immune responses than conventional jabs in a phase…
GSK’s ADC lays down marker for lung cancer scrap with Merck
GSK’s risvutatug rezetecan (ris-rez) has achieved a median overall survival (OS) of 18.5 months in a phase 3…
Roche notches ph. 3 lung cancer win but trails GSK on survival
MediLink has reported phase 3 results on a Roche-partnered antibody-drug conjugate (ADC). The small cell lung cancer (SCLC) trial…
AstraZeneca’s heart failure drug shows promise in ph. 2 trial
AstraZeneca’s oral relaxin agonist delivered encouraging phase 2b results in chronic heart failure, improving measures of cardiac function…
AstraZeneca Falls 1.3% Despite a 34% COPD Breakthrough
This article first appeared on GuruFocus. AstraZeneca (NYSE:AZN), the global oncology and biopharmaceutical company, fell approximately 1.3% to…
GSK and Roche Chinese ADC bets deliver positive phase 3 data in SCLC
Why it matters: For GSK and Roche, the results give them both late-stage contenders in small-cell lung cancer…
AstraZeneca touts Enhertu, Orpathys dual lung cancer wins amid bispecific failure
AstraZeneca reported positive results from two non-small cell lung cancer trials for Enhertu and an Orpathys-Tagrisso combination, although…
GSK to seek FDA approval for Jemperli in high-profile cancer use
In what GSK says represents a potential way to transform treatment for patients with certain types of rectal…
GSK partner Hansoh reports another phase 3 win for priority ADC
Hansoh Pharmaceutical has guided its GSK-partnered, B7-H3-directed antibody-drug conjugate (ADC) to another phase 3 win in China. Weeks after reporting…
AstraZeneca updates Ultomiris HSCT-TMA Phase III data | AZN SEC Filing
FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant…
GSK setback deepens P2X3 cough drug doubts
Why it matters: P2X3 antagonists were expected to create a new treatment class for patients whose cough persists…